Development of human-human hybridoma from anti-Her-2 peptide-producing B cells in immunized NOG mouse.
Exp Hematol
; 34(9): 1240-8, 2006 Sep.
Article
en En
| MEDLINE
| ID: mdl-16939817
ABSTRACT
OBJECTIVE:
Numerous monoclonal antibodies have been developed for the purpose of medical treatments, including cancer treatment. For clinical application, the most useful are human-derived antibodies. In this study, we tried to prepare designed antigen-specific antibodies of completely human origin using immunodeficient mouse.METHODS:
Nonobese diabetic/severe combined immunodeficient/IL-2 receptor gamma null mouse (NOG) mouse was used to reconstitute the human immune system with umbilical cord blood hematopoietic stem cells (CB-NOG mouse) and to prepare human-derived Her-2-epitope-specific antibodies. Hybridoma lines were prepared by fusing the human myeloma cell line Karpas707H.RESULTS:
Serum of immunized NOG mouse contained human-derived immunoglobulin M (IgM) antibodies specific for a short peptide sequence of 20 amino acids, including the epitope peptide of apoptotic Her-2 antibody CH401. Hybridoma lines were successfully prepared with spleen B cells obtained from the immunized CB-NOG mouse. One of these cell lines produced human IgM against the epitope peptide that can recognize surface Her-2 molecule.CONCLUSION:
We could produce human-derived IgM antibody against Her-2 epitope peptide in CB-NOG mouse, succeeding in generation of human hybridoma-secreting IgM against a given peptide.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Péptidos
/
Inmunoglobulina M
/
Linfocitos B
/
Quimera por Trasplante
/
Receptor ErbB-2
/
Epítopos de Linfocito B
/
Hibridomas
/
Anticuerpos Monoclonales
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Exp Hematol
Año:
2006
Tipo del documento:
Article
País de afiliación:
Japón